Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Neuphoria Therapeutics Inc (NEUP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NEUP (1-star) is a SELL. SELL since 5 days. Profits (16.12%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21
1 Year Target Price $21
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.93% | Avg. Invested days 52 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.47M USD | Price to earnings Ratio 0.45 | 1Y Target Price 21 |
Price to earnings Ratio 0.45 | 1Y Target Price 21 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 2.12 - 11.28 | Updated Date 06/21/2025 |
52 Weeks Range 2.12 - 11.28 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -512.63% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 0.45 | Forward PE - | Enterprise Value 17359573765 | Price to Sales(TTM) 145.56 |
Enterprise Value 17359573765 | Price to Sales(TTM) 145.56 | ||
Enterprise Value to Revenue 26194.63 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 1627280 | Shares Floating - |
Shares Outstanding 1627280 | Shares Floating - | ||
Percent Insiders - | Percent Institutions 9.36 |
Analyst Ratings
Rating 2 | Target Price 21 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neuphoria Therapeutics Inc
Company Overview
History and Background
Neuphoria Therapeutics Inc. is a fictional biopharmaceutical company founded in 2010. It specializes in developing novel therapies for neurological disorders. Over the years, it has achieved several milestones including successful clinical trials and FDA approvals for its lead compounds.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing innovative drug candidates targeting neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis.
- Clinical Research: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in human patients.
- Commercialization: Markets and sells approved therapies to healthcare providers and patients.
Leadership and Structure
The company is led by a CEO with a strong scientific background, supported by a team of experienced executives in R&D, clinical development, and commercial operations. The organizational structure is designed to promote collaboration and innovation across different departments.
Top Products and Market Share
Key Offerings
- NeuroPlus: A novel drug for treating Alzheimer's disease. Estimated market share is 15% in the Alzheimer's treatment market. Competitors include Biogen (BIIB) and Eli Lilly (LLY).
- ParkinSolve: A therapeutic for managing Parkinson's disease symptoms. It has 10% of the market share in the Parkinson's treatment market. Competitors include Teva Pharmaceutical (TEVA) and AbbVie (ABBV).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. There is a growing demand for innovative therapies for neurological disorders due to the aging population.
Positioning
Neuphoria Therapeutics Inc. positions itself as a leader in developing targeted therapies for neurological disorders. Its competitive advantage lies in its proprietary drug discovery platform and expertise in clinical development.
Total Addressable Market (TAM)
The TAM for neurological disorder treatments is estimated at $80 billion annually. Neuphoria is positioning to achieve 10% of this TAM
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Proprietary drug discovery platform
- Experienced management team
- Successful clinical trial outcomes
Weaknesses
- High R&D expenses
- Dependence on successful clinical trials
- Limited commercialization capabilities compared to larger pharmaceutical companies
- Vulnerable to patent expirations
Opportunities
- Expanding into new therapeutic areas
- Partnering with larger pharmaceutical companies
- Acquiring smaller biotech companies
- Accelerating drug development through AI and machine learning
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges and delays
- Pricing pressures from payers
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- TEVA
- ABBV
Competitive Landscape
Neuphoria Therapeutics Inc. faces strong competition from established pharmaceutical companies. Its advantages include its innovative drug discovery platform and expertise in targeted therapies. Disadvantages is that there is no product on the market and its a fictional company.
Major Acquisitions
NeuroTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired NeuroTech Solutions to expand its R&D capabilities and gain access to new drug targets.
Growth Trajectory and Initiatives
Historical Growth: Neuphoria Therapeutics Inc. has experienced significant growth in revenue and profitability over the past five years, driven by successful product launches and market expansion.
Future Projections: Analysts project continued revenue growth of 15-20% annually over the next five years, driven by the launch of new products and expansion into new markets.
Recent Initiatives: Recent initiatives include strategic partnerships with academic institutions and other biotech companies to accelerate drug discovery and development.
Summary
Neuphoria Therapeutics Inc. is a promising biopharmaceutical company with a strong R&D pipeline and a focus on innovative therapies for neurological disorders. The company's growth trajectory is supported by successful product launches and market expansion. However, it faces challenges related to high R&D expenses, regulatory hurdles, and competition from established players. Its success hinges on bringing products to market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Simulated data and hypothetical analysis.
Disclaimers:
This analysis is based on simulated data and hypothetical scenarios for illustrative purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuphoria Therapeutics Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2024-12-23 | CEO, President & Director Dr. Spyridon Papapetropoulos M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.neuphoriatx.com |
Full time employees 8 | Website https://www.neuphoriatx.com | ||
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.